Identifying a Vimentin Isoform Linked to Pancreatic Cancer
Author Information
Author(s): Hong Su-Hyung, David E. Misek, Hong Puravs, Eric Hinderer, Robert Giordano, Thomas J. Greenson, Joel K. Brenner, Dean E. Simeone, Diane M. Logsdon, Craig D. Hanash
Primary Institution: University of Michigan Medical School
Hypothesis
Can a specific isoform of vimentin induce an antibody response in pancreatic cancer patients?
Conclusion
The study found that a specific isoform of vimentin elicited an antibody response in 44.4% of pancreatic cancer patients, suggesting its potential as a diagnostic marker.
Supporting Evidence
- 44.4% of pancreatic cancer patients showed autoantibodies against the vimentin isoform.
- Only 5.6% of chronic pancreatitis patients and 0% of healthy controls exhibited reactivity against this isoform.
- The antigenic isoform was expressed at 5–10 fold higher levels in pancreatic tumors compared to other cancers.
Takeaway
Researchers found that a special version of a protein called vimentin can trigger the immune system in some people with pancreatic cancer, which might help doctors find the cancer earlier.
Methodology
The study used a proteomic approach involving 2-D PAGE and Western blot analysis to identify autoantibodies in patient sera against proteins from a pancreatic cancer cell line.
Limitations
The study's findings need further validation in larger cohorts to confirm the specificity of vimentin antibodies to pancreatic cancer.
Participant Demographics
The mean age of pancreatic cancer patients was 65.4 years, with a range of 54–74 years.
Statistical Information
P-Value
0.003
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website